KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Free Cash Flow: 2009-2025

Historic Free Cash Flow for Halozyme Therapeutics (HALO) over the last 17 years, with Sep 2025 value amounting to $175.6 million.

  • Halozyme Therapeutics' Free Cash Flow rose 54.20% to $175.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $602.4 million, marking a year-over-year increase of 53.40%. This contributed to the annual value of $468.4 million for FY2024, which is 25.47% up from last year.
  • Latest data reveals that Halozyme Therapeutics reported Free Cash Flow of $175.6 million as of Q3 2025, which was up 78.88% from $98.1 million recorded in Q2 2025.
  • Halozyme Therapeutics' Free Cash Flow's 5-year high stood at $175.6 million during Q3 2025, with a 5-year trough of $36.4 million in Q2 2021.
  • Over the past 3 years, Halozyme Therapeutics' median Free Cash Flow value was $113.9 million (recorded in 2024), while the average stood at $115.3 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first surged by 1,952.18% in 2021, then slumped by 43.40% in 2022.
  • Quarterly analysis of 5 years shows Halozyme Therapeutics' Free Cash Flow stood at $82.4 million in 2021, then declined by 4.45% to $78.7 million in 2022, then rose by 26.77% to $99.8 million in 2023, then surged by 75.84% to $175.4 million in 2024, then soared by 54.20% to $175.6 million in 2025.
  • Its Free Cash Flow stands at $175.6 million for Q3 2025, versus $98.1 million for Q2 2025 and $153.3 million for Q1 2025.